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RESEARCH ARTICLE Open Access
High prevalence and clonal dissemination
of OXA-72-producing Acinetobacter
baumannii in a Chinese hospital: a cross
sectional study
Yong Chen1†, Yuying Yang2,3†, Lin Liu1,4†, Guangbin Qiu5, Xuelin Han1, Shuguang Tian1, Jingya Zhao1,
Fangyan Chen1, Hajo Grundmann6,7, Haifeng Li8*, Jinke Sun2,3,9* and Li Han1*
Abstract
Background: Carbapenem resistance in Acinetobacter baumannii in China was mainly mediated by OXA-23-like
carbapenemases, while OXA-24/40-like carbapenemases were rarely identified. OXA-72 is one variant of OXA-24/40-like
carbapenemases. This study aimed to demonstrate the epidemiology and characterizations of OXA-72-producing
A. baumannii in a Chinese hospital.
Methods: A total of 107 clinical A. calcoaceticus-A. baumannii (Acb) complex isolates were collected in a Chinese
hospital during between 2014 and 2016. These isolates were identified using Vitek 2 system and gyrB multiplex PCR.
Vitek 2 system was used for antibiotic susceptibility testing. Genes encoding for major classes of carbapenemases
were investigated by PCR. Rep-PCR was used for genotyping of all the A. baumannii isolates. The risk factors for
carriage of OXA-72-producing or OXA-23-producing A. baumannii were analyzed through univariate and multivariate
logistic regression.
Results: Of the 107 Acb isolates collected, 101 isolates (94.4%) and 6 isolates (5.6%) were identified as A. baumannii
and A. pittii, respectively. 78 A. baumannii isolates (77.2%) were carbapenem resistant and mainly cultured from
intensive care unit (ICU). blaOXA-72 and blaOXA-23 genes were identified in 45(57.7%) and 33(42.3%) carbapenem-resistant
A. baumannii (CRAB), respectively. Multivariate risk factor analyses showed that prior carbapenem usage and
nasogastric intubation were significantly associated with carriage of OXA-72-producing A. baumannii or
OXA-23-producing A. baumannii. Rep-PCR analysis showed that 9 and 22 Rep-PCR types were assigned to 78 CRAB
isolates and 23 carbapenem-susceptible A. baumannii (CSAB) isolates, respectively. A higher diverstiy of Rep-PCR
patterns was observed among OXA-72-producing A. baumannii isolates than OXA-23-producing A. baumannii isolates,
but all of them belonged to the same clone complex. MLST analysis suggested that the OXA-72 isolates from this
study correspond to CC92/CC2 clone complex.
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Conclusions: This study demonstrates high prevalence and potential clonal spread of closely related genotypes of
OXA-72-producing A. baumannii within a Chinese hospital. Continuous surveillance is necessary to monitor the
dissemination of these strains in other healthcare settings to guide infection control policies in order to curb the
spread of this bacterium.
Keywords: Acinetobacter baumannii, OXA carbapenemases, Risk factor, Molecular typing, Clone dissemination
Background
Acinetobacter is a gram-negative coccobacillus that has
rapidly emerged as one of the most common nosocomial
pathogens worldwide [1]. There are currently at least 31
described Acinetobacter genomic species [2], of which
A. calcoaceticus, A. baumannii, A. pittii, and A. noso-
comialis are very closely related, and difficult to distin-
guish from each other by phenotypic properties [3]. A.
calcoaceticus-A. baumannii (Acb) complex has therefore
been proposed to refer to these species [2]. Nevertheless,
A. baumannii is the most clinically relevant and is notori-
ous for its ability to accumulate diverse mechanisms of
resistance [4, 5].
The carbapenem class of antibiotics is considered as the
last-resort choice when treating Acinetobacter infections.
However, an increasing prevalence of carbapenem resist-
ance has been observed in clinical A. baumannii isolates
from many parts of the world. Carbapenem-associated
multiclass resistance among 55,330 U.S. A. baumannii
isolates from The Surveillance Network database has
increased from 20.6% in 2002 to 49.2% in 2008 [6]. In
China, the resistance rate of clinical A. baumannii to car-
bapenem gradually increased from < 10% in 2000 to > 60%
at present [7, 8]. The major mechanism of carbapenem
resistance is production of OXA β-lactamases, which are
clustered in three major groups, OXA-23-like, OXA-24/
40-like, and OXA-58-like [9–11].
OXA-24/40 β-lactamase was first identified in A.
baumannii from Spain in 1997 [12]. After that, A fur-
ther 6 enzyme variants have since been discovered,
including OXA-72 [11]. Unlike OXA-23-like, OXA-24/40
β-lactamases were less commonly identified in carba-
penem resistant Acinetobacter spp. isolates [13]. A large
surveillance of OXA-type β-lactamase gene clusters for
a total of 2880 Acinetobacter spp. isolates collected
from 23 Chinese provinces found that blaOXA-23-like and
blaOXA-24/40-like genes were identified in 1316 isolates
(45.7%) and 11 isolates (0.4%), respectively [14]. Therefore,
OXA-24/40-like β-lactamases were only responsible for a
small number of carbapenem-resistance isolates in China,
their dissemination and epidemiology in healthcare set-
tings deserves further surveillance and investigation.
This study aimed to demonstrate the occurrence, clin-
ical manifestation and genotypic characterizations of
OXA-72-producing A. baumannii in a Chinese hospital.
Methods
Study settings and isolates information
A total of 107 clinical Acb complex isolates from 107
patients were collected at a tertiary-care comprehensive
hospital in northeastern China with 1800 beds, from Oct
2014 to Oct 2016. These isolates were recovered from
various specimens including sputum, blood, urine, pleural
fluid, secretions and throat swab sample. For each patient,
only a single colony of the first isolate was selected for
subsequent analysis. All the clinical isolates were stored
at − 80 °C until use. Data for each isolate and each pa-
tient were obtained through review of microbiology lab
results and medical records. Risk factor data, including
ICU stay, presence of invasive procedures and anti-
biotic treatment, referred to those which were present
before the isolation of the index Acinetobacter strains.
All data were anonymously collected and interpreted.
Strain identification and in vitro antibiotic susceptibility
testing
Identification of Acb complex isolates was initially per-
formed using automated identification systems the VITEK
2 compact system (BioMérieux, Craponne, France). Fur-
ther identification of the Acb complex to the species level
was performed by gyrB multiplex PCR [15, 16].
In vitro susceptibilities to ampicillin-sulbactam, piperacillin-
tazobactam, ceftazidime, cefepime, meropenem, imipe-
nem, gentamicin, amikacin, ciprofloxacin, levofloxacin,
colistin, minocyline were determined by the VITEK 2
compact system (BioMérieux, Craponne, France). Escheri-
chia coli (ATCC 25922) and Pseudomonas aeruginosa
(ATCC 27853) were used as quality control strains. Results
were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI, 2016) guidelines.
Detection of carbapenemases genes
One white loop (1 μl) of 24 h plate culture of Acineto-
bacter bacteria was resuspended in 200 μl of sterilized
and DNA free water. The bacterial suspensions were
then heated for 10 min at 96 °C and centrifuged 5 min
at 13000 rpm. The supernatant was used as the genomic
DNA for the following molecular experiments.
Genes encoding for major classes of A, B, and D carbape-
nemases for all the Acb isolates were investigated by PCR.
The presence of blaOXA-23-like, blaOXA-24-like, blaOXA-51-like,
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and blaOXA-58-like genes were detected through multiplex
PCR assay [17]. Metallo-β-lactamase encoding genes,
blaNDM-like, blaIMP-like and blaVIP-like, were detected with
PCR conditions and primers as previously described [18].
The blaOXA-24-like variant was further identified through
PCR and DNA sequencing as described [19].
Molecular typing
Rep-PCR was used for genotyping of all the A. bauman-
nii isolates, using the primer pair REP 1(5’-IIIGCGC
CGICAGGC-3′) and REP 2(5’-ACGTCTTATCAGGC
CTAC-3′) [20]. The conditions for PCR and the gel elec-
trophoresis were the same as previously described [21].
Rep-PCR results of each isolate was compared to all of
the other isolates in a pairwise manner, isolates with
identical band patterns were considered to be of identi-
cal Rep-PCR types. A minimum spanning tree was cre-
ated to show the differences between patterns through
BioNumerics 6.6 software (Applied Maths, Kortrijk,
Belgium). The spanning tree was limited to those pat-
terns that differ by a single band, two Rep-PCR types
that differ by two or more bands were connected. Nine
blaOXA-24-like gene positive representative isolates from
each different Rep-PCR type were randomly chosen for
multilocus sequence typing (MLST) analysis according
to ‘Pasteur’ scheme [22].
A review of literature
Currently, there were two MLST schemes available for
Acinetobacter. In order to differentiate between the two
schemes, STs and CCs were designated as STB/CCB for
the Bartual scheme and STP/CCP for the Pasteur scheme.
A search of previous published papers giving the MLST
results of OXA-24/40-like producing Acinetobacter spp.
was conducted to illustrate the population structure of
OXA-24/40 strains from different countries. The MLST
data from ‘Pasteur’ scheme and ‘Bartual’ scheme were
separately analyzed by Bionumerics 6.6 and presented
as a minimum spanning tree for categorical data with
default settings.
Statistical analysis
Statistical analyses were performed using SPSS 19.0
(IBM, Armonk, NY, USA). The comparisons of patients’
characterics were conducted by chi-square test or
Mann-Whitney U test. The risk factors for carriage of
blaOXA-72-positive or blaOXA-23-like-positive A. bauman-
nii were analyzed through univariate and multivariate lo-
gistic regression. In multivariate logistic regression, ICU
stay and length of ICU stay were not included as they
were highly associated with many other predisposing
factors, including invasive procedures and antibiotic
use. The index of diversity and the 95% confidence
intervals (CIs) were calculated as described previously
[23]. P values < 0.05 are considered statistically significant.
Results
Of the 107 Acinetobacter isolates, 101 isolates (94.4%)
and 6 isolates (5.6%) were identified as A. baumannii
and A. pittii, respectively. Five A. pittii isolates were
susceptible to all the antibiotics tested and one isolate
exhibited an intermediate resistance phenotype to minocy-
cline. Among the 101 A. baumannii isolates, 78 isolates
(77.2%) were resistant to carbapenems (meropenem or imi-
penem). The rates of resistance to piperacilin/tazobactam,
ampicillin/sulbactam, amikacin, gentamicin, ceftazidime,
ciprofloxacin and levofloxacin in A. baumannii were all
above 60%, as most of the carbapenem-resistance isolates
exhibited a multidrug resistance phenotype. Four A. bau-
mannii isolates were resistant to polymyxin.
The 107 Acinetobacter isolates were cultured from
71 male and 46 female patients. Fifty-one isolates
were cultured from patients in ICU and all these iso-
lates were carbapenem-resistant. The detection of car-
bapenemase genes showed that 33 (42.3%) of the 78
carbapenem-resistant A. baumannii (CRAB) were positive
for the blaOXA-23-like gene, while the other 45 isolates
(57.7%) were positive for the blaOXA-24/40-like gene. All
these isolates harboured blaOXA-51-like gene. DNA se-
quencing showed that all the blaOXA-24/40-like ampli-
cons belonged to blaOXA-72 (GenBank accession number
Table 1 Characteristics of 101 patients colonized or infected with Acinetobacter baumannii in a Chinese hospital







Age, median years(range) 77(21,94) 76(2,96) – 0.463
Male Gender, n(%) 50(64.1) 19(82.6) 2.81 0.094
Length of hospital stay, median days (range) 11(1,3650) 8(1,1400) – 0.786
ICU stay, n (%) 49(62.8) 1(4.3) 24.30 < 0.001
Associated with an infection, n(%) 67(85.9) 17(73.9) 1.07 0.302
All-cause mortality of patients 14 days after isolation of A. baumannii, n(%) 16(20.5) 4(17.4) 0.001 0.974
ICU intensive care unit
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MF781069). The blaOXA-58-like gene was detected in one
carbapenem-susceptible A. baumannii (CSAB) isolate,
the MICs for imipenem and meropenem were 0.5 μg/ml
and 0.25 μg/ml, respectively. None of these Acinetobacter
isolates were positive for blaIMP-like, blaVIM-like or blaNDM-like
genes.
Eighty-four (83.2%) of 101 A. baumannii isolates were
associated with an infection (primarily low respiratory
tract infection) and antibiotic treatment, while the other
27 isolates were just colonized. The characterics of 101 pa-
tients colonized or infected with A. baumannii were shown
in Table 1. There were no significant differences over age
and gender distribution among patients colonized or in-
fected with CRAB and CSAB strains. More than 60% of the
CRAB patients stayed at ICU at the time of bacteria isola-
tion, while only one CSAB patient stayed at ICU.
The results of univariate logistic analysis showed that
there were many common risk factors for carriage of
OXA-72-producing A. baumannii or OXA-23-producing
A. baumannii, such as ICU stay, mechanical ventilation,
nasogastric intubation and carbapenem treatment
(Table 2). In multivarite analysis, prior carbapenem
usage and nasogastric intubation were significantly as-
sociated with carriage of OXA-72-producing A. bauman-
nii or OXA-23-producing A. baumannii. An additional
risk factor, urinary catheter, was also significantly associ-
ated with carriage of blaOXA-23-like-positive A. baumannii
(Table 3).
The results of Rep-PCR patterns and corresponding
strain information for the 101 A. baumannii were shown
in Table 4. In total, 9 Rep-PCR types were assigned to 78
CRAB isolates, while 22 Rep-PCR types were assigned to
23 CSAB isolates. The index of diversity (DI) for CRAB
was 0.750 (95% CI: 0.671–0.829), which was significantly
lower than for CSAB (DI = 0.996, 95% CI: 0.986–1.006).
Twenty-six and 7 OXA-23-producing A. baumannii iso-
lates were identified as Rep-PCR type 1 and 2, respect-
ively, while 45 OXA-72-producing A. baumannii isolates






OR(CI 95%) P value OXA-23 cases
(n = 33)
OR(CI 95%) P value
Age, median(range) 76(2,96) 78(28,94) 1.02(1.00,1.05) 0.081 78(21,90) 1.00(0.99,1.03) 0.460
Male gender, n(%) 22(75.9) 27(60.0) 0.32(0.09,1.08) 0.067 23(69.7) 0.48(0.13,1.79) 0.484
ICU stay, n (%) 1(4.3) 27(60.0) 33.00(4.08,267.04) 0.001 22(66.7) 44.00(5.23,370.52) < 0.001
Length of stay in the ICU (days),
median(range)
0(0,2) 5(0,100) 2.29(1.20,4.37) 0.012 3(0,100) 2.29(1.03,5.08) 0.042
Predisposing factors
Urinary catheter 9(39.1) 27(60.0) 2.33(0.84,6.52) 0.106 23(69.7) 3.58(1.17,10.96) 0.026
Mechanical ventilation 2(8.7) 18(40.0) 7.00(1.46,33.59) 0.015 14(42.4) 7.74(1.55,38.56) 0.013
Central venous catheter 5(21.7) 14(31.1) 1.63(0.50,5.26) 0.417 17(51.5) 3.83(1.15,12.74) 0.029
Tracheostomy 1(4.3) 10(22.2) 6.29(0.75,52.56) 0.090 11(33.3) 11.00(1.31,92.63) 0.027
Transfusion 1(4.3) 5(11.1) 2.75(0.30,25.05) 0.369 7(21.2) 5.92(0.68,51.92) 0.108
Nasogastric intubation 4(17.4) 28(62.2) 7.82(2.27,26.91) 0.001 19(57.6) 6.45(1.79,23.19) 0.004
Cephalosporin 12(52.2) 15(33.3) 0.46(0.16,1.27) 0.136 12(36.4) 0.53(0.17,1.55) 0.242
β-lactam/β-lactamase inhibitor
combinations
12(52.2) 24(53.3) 2.61(0.90,7.57) 0.077 12(36.4) 1.31(0.42,4.07) 0.645
Quinolone 3(13.0) 19(42.2) 4.87(1.26,18.79) 0.022 10(30.3) 2.90(0.70,12.02) 0.143
Carbapenem 4(17.4) 21(46.7) 4.16(1.22,14.18) 0.023 20(60.6) 7.31(2.02,26.40) 0.002
aControl cases: 23 patients colonized or infected with carbapenem-susceptible Acinetobacter baumannii
ICU intensive care unit
Table 3 Multivariate logistic analysis of risk factors for carriage of OXA-72-producing Acinetobacter baumannii or OXA-23-producing
A. baumannii
Characteristics OXA-72 cases OXA-23 cases
OR(CI 95%) P value OR(CI 95%) P value
Urinary catheter – – 4.94(1.61–21.07) 0.031
Nasogastric intubation 7.65(2.14,27.36) 0.002 7.95(1.79–35.34) 0.006
Carbapenem usage 4.02(1.07,15.06) 0.039 10.05(2.21–45.58) 0.003
Chen et al. BMC Infectious Diseases  (2018) 18:491 Page 4 of 11











IMP MEM CAZ FEP AMK GEN CIP LVX TZP SAM MH COL
N1312 1 NA blaOXA-23 R R R R R R R R R R S S
N1314 1 NA blaOXA-23 R R R I R R R R R R S S
N1316 1 NA blaOXA-23 R R R R R R R R R R S S
N1318 1 NA blaOXA-23 R R R I S R R R R I S S
N1352 1 NA blaOXA-23 R R R R R R R I R R S S
N1359 1 NA blaOXA-23 R R R R R R R I R R S S
N1362 1 NA blaOXA-23 R R R R R R R R R R S S
N1369 1 NA blaOXA-23 R R R R R I R I R R S S
N1371 1 NA blaOXA-23 R R R R R R R I R R S S
N1383 1 NA blaOXA-23 R R R R R R R R R R S S
N1384 1 NA blaOXA-23 R R R R R R R R R R S S
N1386 1 NA blaOXA-23 R R R R R R R I R R S R
N1395 1 NA blaOXA-23 R R R R R R R R R R S S
N1396 1 NA blaOXA-23 R R R R R R R R R R S S
N1398 1 NA blaOXA-23 I R R R R R R R R I S S
N1401 1 NA blaOXA-23 R R R R R R R R R I S S
N1407 1 NA blaOXA-23 R R R R R R R R R R S S
N741 1 NA blaOXA-23 R R R R R R R R R R S S
N747 1 NA blaOXA-23 R R R I R R R R R S I S
N748 1 NA blaOXA-23 R R R R R R R R S R I S
N749 1 NA blaOXA-23 R R R R R R R R R R S S
N751 1 NA blaOXA-23 R R R R R R R R R R S S
N752 1 NA blaOXA-23 R R R R R R R R R R I S
N756 1 NA blaOXA-23 R R R I R R R R R S S S
N762 1 NA blaOXA-23 R R R R R R R R R R I S
N764 1 NA blaOXA-23 R R R R R R R R R R I S
N1304 1 NA blaOXA-72 R R R S R R R I R I S S
N1307 1 2 blaOXA-72 R R R I R R R R R I S S
N1309 1 NA blaOXA-72 R R R R R R R I R R S S
N1311 1 NA blaOXA-72 R R R I R R R I R I S S
N1315 1 NA blaOXA-72 R R R R R R R R R R S S
N743 1 NA blaOXA-72 R R R R R R R R R R R S
N745 1 NA blaOXA-72 R R R I R R R R R I I S
N750 1 NA blaOXA-72 R R R I R R R R R R I S
N754 1 NA blaOXA-72 R R R I R R R R R I S S
N1412 2 NA blaOXA-23 I R R R R R R R R R S S
N1419 2 NA blaOXA-23 I R R R R R R R R R S S
N1420 2 NA blaOXA-23 R R R R R R R R R S S S
N1424 2 NA blaOXA-23 I R R R R R R R R R S S
N1428 2 NA blaOXA-23 R R R R R R R R R I S S
N1447 2 NA blaOXA-23 R R R R R R R I R R S S
N1449 2 NA blaOXA-23 R R R R R R R I R R S S
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IMP MEM CAZ FEP AMK GEN CIP LVX TZP SAM MH COL
N1372 2 NA blaOXA-72 R R R I R R R R R R I S
N1411 2 NA blaOXA-72 R R R I R R R R R R S S
N1425 2 2 blaOXA-72 R R R S R R R R R I S S
N1446 2 NA blaOXA-72 R R R I R R R R R R S S
N1451 2 NA blaOXA-72 R R R R R R R R R R I S
N1348 3 NA blaOXA-72 R R R I R R R R R R S S
N1349 3 NA blaOXA-72 R R R I R R R R R R S S
N1368 3 NA blaOXA-72 R R R I R R R R R R S S
N1376 3 NA blaOXA-72 R R R S R R R R R R S S
N1378 3 NA blaOXA-72 R R R I R R R R R R S S
N1421 3 2 blaOXA-72 R R R I R R R R R I S S
N1427 3 NA blaOXA-72 R R R I R R R R R R S S
N1429 3 NA blaOXA-72 R R R I S S R I R R S S
N1432 3 NA blaOXA-72 R R R I R R R R R S S S
N1436 3 NA blaOXA-72 R R R R R R R R R R S S
N1437 3 NA blaOXA-72 R R R I R R R R R R S S
N1365 4 NA blaOXA-72 R R R I R R R R R R S S
N1366 4 NA blaOXA-72 R R R R R R R R R R S S
N1422 4 2 blaOXA-72 R R R S R R R I R I S S
N1434 4 NA blaOXA-72 R R R I R R R R R R S S
N1361 5 NA blaOXA-72 R R R I R R R R R R S S
N1375 5 NA blaOXA-72 R R R R R I R R R R S S
N1380 5 NA blaOXA-72 R R R S R R R R R R S S
N1381 5 NA blaOXA-72 R R R S R R R R R R S S
N1397 5 2 blaOXA-72 R R R I R R R R R R S S
N1400 5 NA blaOXA-72 R R R I R R R R R R S S
N1350 6 NA blaOXA-72 R R R I R R R R R R S S
N1353 6 2 blaOXA-72 R R R R R R R R R R S S
N1370 6 NA blaOXA-72 R R R I R R R R R R I S
N1391 7 2 blaOXA-72 R R R R R R R R R R S S
N1357 8 2 blaOXA-72 R R S S S R R R I S S S
N1374 8 NA blaOXA-72 R R R I R R R R R R S S
N1379 8 NA blaOXA-72 R R R I R R R R R R S S
N1392 8 NA blaOXA-72 R R R S R R R R R R S S
N1409 8 NA blaOXA-72 R R R S R R R I R I S S
N1382 9 2 blaOXA-72 R R R S R R R R R R S S
N1415 10 NA None S S S S S S S S S S S S
N1441 11 NA None S S S S S R S S S R S S
N1443 12 NA None S S S S S S S S S S S S
N1408 13 NA None S S S S S S S S S S S S
N1306 14 NA None S S S S S S S S S S S S
N1414 15 NA None S S S S S S S S S S S S
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were distributed in the 9 Rep-PCR types. Minimum span-
ning tree analysis of Rep-PCR patterns showed that all the
78 CRAB isolates were clustered into one clone complex,
while most of the CSAB isolates were not connected to
each other (Fig. 1). MLST analysis showed that all the 9
representative OXA-72 isolates in this study belong to
ST2 (Table 4).
A literature review of previous published MLST data
showed that there were at least 19 ST types (Bartual
scheme) for 29 OXA-24/40-like producing Acinetobacter
spp. isolates from 11 countries and 21 ST types (Pasteur
scheme) for 52 OXA-24/40-like producing Acinetobacter
spp. isolates from 15 countries. Minimum spanning tree
analysis of these isolates based on two different MLST
schemes was shown in Fig. 2, which suggested that
CC92B/CC2P represented the predominant clone for the
OXA-24/40-like producing Acinetobacter spp. isolates
from around the world.
Discussions
Carbapenem-resistant Acinetobacter spp. (mainly CRAB)
are increasingly recognized as major nosocomial patho-
gens and considered to be serious threat for human health
by US Centers for Disease Control and Prevention and
World Health Organization [24, 25]. OXA-23-like carba-
penemases were the main reason for the high prevalence
and wide dissemination of CRAB from many parts of the
world, including China [14, 26, 27]. OXA-24/40-like car-
bapenemases, which have been reported to be associated
with outbreak of nosocomial infection in United States,
Spain, Turkey and Ecuador [28–31], accounted for only a
small part of CRAB in China [14, 32]. OXA-72, which was
first identified in 2004 in an A. baumannii isolate from
Thailand, belonged to one of the most important variant
of OXA-24/40-like carbapenemases [29]. This study re-
ported firstly a high prevalence and clonal dissemination
of OXA-72-producing A. baumannii in a hospital from
northeastern China.
Carbapenem resistance in A. baumannii was not sig-
nificantly associated with 14-day mortality in this study
(Table 1), which is in accordance with previous studies
[33, 34]. However, carbapenem resistance limits the
available therapeutic agents, makes the infection difficult
to treat, and might be associated with an additional cost
of hospitalization [34]. In this study, there was no sig-
nificant difference over length of hospital stay for carba-
penem resistance and susceptible A. baumannii, which
might be related with the limited sample size.
In vitro antimicrobial susceptibility testing showed that
OXA-72-producing A. baumannii and OXA-23-producing
A. baumannii exhibited similar multidrug resistance profile,
suggesting that they could not be differentiated through











IMP MEM CAZ FEP AMK GEN CIP LVX TZP SAM MH COL
N1363 16 NA None S S S S S S S S S S S S
N1389 17 NA None S S S S S S S S S S S S
N1405 18 NA None S S S S S S S S S S S S
N1406 18 NA None S S S S S S S S S S S R
N1377 19 NA None S S R R R R R R R R S S
N1390 20 NA blaOXA-58 S S S S S R S S S S S S
N1448 21 NA None S S S S S R R R S S S R
N1354 22 NA None S S S S S S S S S S S S
N746 23 NA None S S S S S S S S S I S S
N1364 24 NA None S S S S S S S S S S S S
N1393 25 NA None S S S S S S S S S S S S
N1351 26 NA None S S S S S S S S S S S S
N1399 27 NA None S S S S S S S S S S S S
N1305 28 NA None S S S S S S S S S S S S
N1387 29 NA None S S S S S S S S S S S S
N744 30 NA None S S S S S S S S S S S R
N1423 31 NA None S S S S S S S S S S S S
NA not available, IMP imipenem, MEM meropenem, CAZ ceftazidime, FEP cefepime, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin, TZP
piperacillin-tazobactam, SAM ampicillin-sulbactam, MH minocyline, COL colistin, R resistant, I intermediate, S susceptible
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detection of antimicrobial phenotype. The risk factor ana-
lyses implicated that admitted into ICU and length of ICU
stay were the most important risk factors for carriage of
OXA-72-producing A. baumannii and OXA-23-producing
A. baumannii, as ICU patients are always critical ill and
subjected to a lot of risk factors for the acquisition of multi-
drug resistance organisms (MDROs) [35]. When ICU stay
was removed for multivariable analyses, nasogastric intub-
ation and carbapenem use were significantly associated
with acquisition of both classes of CRAB, which is in
accordance with previous studies [36–38]. The reason
for why urinary catheter was significantly associated
with carriage of OXA-23-producing A. baumannii,
but not OXA-72-producing A. baumannii deserves
further investigation. One possible explanation was
that the complex conditions and combined therapy of
ICU patients compromised the accuracy of multiple
logistics analysis, urinary catheter might be just an indica-
tor for critical ill patients who have a high probability of
acquiring certain MDROs through contaminated environ-
ment or nursing behavior.
CC92B/CC2P was by far the largest and most widely dis-
tributed A. baumannii clone in the world, especially among
OXA-23-producing A. baumannii [27, 39, 40]. Although
not so widely disseminated, CC92B/CC2P was still the most
important clone in OXA-24/40-producing A. baumannii
Fig. 1 Minimum spanning tree of 101 Acinetobacter baumannii isolates based on Rep-PCR patterns. Each circle represents one unique genotype.
OXA-72-producing carbapenem-resistant A. baumannii (CRAB), OXA-23-producing CRAB and carbapenem-susceptible A. baumannii (CSAB) isolates
are indicated with red, green, and blue colors, respectively. The size of each circle corresponds to the number of isolates. The lines connecting
the circles indicate those patterns that differ by a single band. R: carbapenem-resistant strains. S: carbapenem-susceptible strains
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(Fig. 2). The Rep-PCR and MLST analysis of A. baumannii
in this study suggested that OXA-72-producing and
OXA-23-producing A. baumannii isolates were genetically
related and belonged to the same clone, CC92B/CC2P. It
seems that OXA-72-producing A. baumannii has already
become endemic in the ICU since 2014, as most of
these isolates were continuously cultured without obvious
clustering of isolation time. Enhanced infection control
measures, such as hand hygiene education programs, en-
vironmental cleaning, antimicrobial stewardship, contact
precautions [41], have to be implemented in ICU of this
hospital in order to reduce the wide spread of high risk
clone, CC92B/CC2P, which represents the most prevalent
clone of CRAB in Chinese hospitals.
There are some limitations for this study. The first is
the inclusion criteria of Acb complex strains, it has been
demonstrated that a single patient may have more than
one genetic type of Acinetobacter [42, 43]. To avoid the
problem of duplicate data, this study adopted a simple
inclusion method of allowing only a single isolate per
patient. it might limit the ability to monitor the dynamic
changes and complex conditions in patients who may be
at particular risk of acquiring antibiotic resistant strains
through cross-infection or the development of resistance
during antibiotic treatment [44]. Another limitation comes
from the design of this study, as this is just an one-center
study, the epidemiological characterizations of OXA-72
strains in this study might not be generalized to other
healthcare settings in China.
Conclusions
This study described firstly a high prevalence of
OXA-72-producing A. baumannii in ICU of a Chinese
hospital, which have circulated in this ICU through clonal
dissemination for at least two years. Strict infection con-
trol measures must be implemented to contain the on-
going dissemination of OXA carbapenemases-producing
A. baumannii in Chinese ICUs.
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